Quick Facts
  • Primary Location:
    Barbara Ann Karmanos Cancer Institute
  • Expertise:
    Lung Cancer
    Immunotherapy
  • Speciality:
    Medical Oncology
  • Gender:
    Female
  • Language:
    English, Japanese
  • Med School:
    St. Marianna University School of Medicine, Japan

Get to Know Dr. Misako Nagasaka

Dr. Misako Nagasaka plays a key role in the multidisciplinary treatment of thoracic and head-and-neck malignancies at the Barbara Ann Karmanos Cancer Institute, specializing in molecular targeting and novel immunotherapy.

With an unusual background that includes philosophy and ethics, Nagasaka is known for an ability to put patients at ease, fully educating them on their treatment options with her personalized approach.

She has more than a decade of experience in treating lung cancer and mesothelioma patients, exploring options that go well beyond standard chemotherapy.

Nagasaka’s research involves novel clinical trials that have advanced the treatment of lung cancer with various immunotherapy combinations. She works closely with surgical oncologists, radiologists and pathologists at Karmanos to individualize treatment for each patient.

She also serves as an assistant professor of oncology at Wayne State University.

Contact Misako Nagasaka

Specialties of Dr. Misako Nagasaka

Dr. Misako Nagasaka’s Experience and Medical Education

  • Barbara Ann Karmanos Cancer Institute
  • Beth Israel Medical Center in New York (Residency)
  • National Center for Global Health and Medicine, Tokyo (Residency)
  • Karmanos Cancer Institute (Hematology and oncology fellowships)
  • St. Marianna University School of Medicine, Japan

Awards and Other Recognitions

  • N Program Scholar Award, Tokio Marine Foundation
  • St. Marianna University Scholarship Award
  • American Society of Clinical Oncology (Member)
  • American College of Physicians (Member)
  • American Board of Internal Medicine (Member)

Publications of Dr. Misako Nagasaka

  • Nagasaka, M. et al. (2020, May 11). Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1–associated myelopathy/tropical spastic paraparesis. Proceedings of the National Academy of Sciences.
  • Nagasaka, M. et al. (2019, June 18). A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Dovepress.
  • Abdallah, N. et al. (2018, July 17). Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Dovepress.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?